Reading BKYI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BKYI free→Reading BKYI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BKYI free→QuarterlyIQ Insights · BKYI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 5, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the Listings Qualifications Department of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 with the U.S. Securities and Exchange Commission (the “ SEC ”) as required by Nasdaq Listing Rule 5250(c)(1) (the “…
Results of Operations and Financial Condition. On May 18, 2026 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter 2026. A copy of the press release issued by the Company on May 18, 2026 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”), as the Company’s closing bid price was not at least $1.00 per share for 10 consecutive business days as of May 4, 2026. As a result, the Compan…
Material Modification to Rights of Security Holders. To the extent required by
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 16, 2026, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report…
Results of Operations and Financial Condition. On April 16, 2026, BIO-key International, Inc. (the “Company”) issued a press release which included information about its results of operations for its first quarter ended March 31, 2026. A copy of the press release issued by the Company on April 16, 2026 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Ex…
Results of Operations and Financial Condition. On March 31,2026, BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and year ending December 31, 2025. A copy of the press release issued by the Company on March 31, 2026, is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…
Results of Operations and Financial Condition. On March 3, 2026 BIO-key International, Inc. (the “Company”) issued a press release containing financial results for its year end 2025 cash position. A copy of the press release issued by the Company on March 3, 2026 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
Results of Operations and Financial Condition. On November 14, 2025 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter 2025. A copy of the press release issued by the Company on November 14, 2025 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on May 9, 2025, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company did not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”), as the Company’s closing bid price…
Entry into a Material Definitive Agreement. Warrant Exercise Agreement On October 27, 2025, BIO-key International, Inc. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing institutional investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of 3,091,668 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), which were originally issued to the Investor on January 15,…
Unregistered Sale of Equity Securities. Warrant Exercise Agreement The information in
Entry into a Material Definitive Agreement. The information provided in
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 2025, BIO-key International, Inc. (the “Company,” “we” or “us”) entered into and closed a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC, an existing lender of the Company (the “Lender”), which provided for the issuance of a $1,130,000 principal amount senior secured promissory note (the “Note”). The Note carries an original is…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. BIO-key International, Inc. (the “ Company ”) held its Annual Meeting of Stockholders (the “ Annual Meeting ”) on Friday, August 8, 2025. At the Annual Meeting, the stockholders approved: (i) an amendment to the BIO-key International, Inc. 2023 Stock Incentive Plan; and (ii) an amendment to the BIO-key International, Inc. 2021 Employee Stock Purcha…
Results of Operations and Financial Condition. On August 13, 2025 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter 2025. A copy of the press release issued by the Company on August 13, 2025 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 9, 2025, the Company received notice from the staff of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company’s closing bid price for the last 30 consecutive business days was less than $1.00 per share. As a result, the Company does not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 17, 2025, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“ SEC ”), due to the Company’s failure to timely…
Results of Operations and Financial Condition. On March 27, 2025, BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and year ending December 31, 2024. A copy of the press release issued by the Company on March 27, 2025, is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…
Unregistered Sale of Equity Securities. Warrant Exercise Agreement The information in
Entry into a Material Definitive Agreement. Warrant Exercise Agreement On January 15, 2025, BIO-key International, Inc. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing institutional investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of 2,061,112 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at an exercise price of $1.85 per share which were originall…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'expensive' to 'inexpensive'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.